Insider Trading Alert - WST, COG, REGI, EEFT And EVR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 12, 2013, 237 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $356,344,136.36.

Highlighted Stocks Traded by Insiders:

West Pharmaceutical Services (WST) - FREE Research Report

Lennartz Heino who is President Europe at West Pharmaceutical Services sold 5,102 shares at $46.70 on Nov. 12, 2013. Following this transaction, the President Europe owned 18,961 shares meaning that the stake was reduced by 21.2% with the 5,102 share transaction.

The shares most recently traded at $46.79, up $0.09, or 0.19% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 15,200
  • 12-Week # shares sold: 27,083
  • 24-Week # shares sold: 30,083

The average volume for West Pharmaceutical Services has been 257,200 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are up 71.14% year to date as of the close of trading on Tuesday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 30.2. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Cabot Oil & Gas Corporation (COG) - FREE Research Report

Kelley Robert who is Director at Cabot Oil & Gas Corporation bought 14,000 shares at $33.05 on Nov. 12, 2013. Following this transaction, the Director owned 486,596 shares meaning that the stake was reduced by 2.96% with the 14,000 share transaction.

The shares most recently traded at $33.95, up $0.90, or 2.65% since the insider transaction. Historical insider transactions for Cabot Oil & Gas Corporation go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 7,922

The average volume for Cabot Oil & Gas Corporation has been 5.1 million shares per day over the past 30 days. Shares are up 34.78% year to date as of the close of trading on Tuesday.

Cabot Oil & Gas Corporation, an independent oil and gas company, engages in the development, exploitation, exploration, production, and marketing of natural gas, crude oil, and natural gas liquids in the United States. The stock currently has a dividend yield of 0.24%. The company has a P/E ratio of 58.8. Currently there are 12 analysts that rate Cabot Oil & Gas Corporation a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COG - FREE

TheStreet Quant Ratings rates Cabot Oil & Gas Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cabot Oil & Gas Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Renewable Energy Group (REGI) - FREE Research Report

Jackson Michael A who is Director at Renewable Energy Group sold 7,923 shares at $13.00 on Nov. 12, 2013. Following this transaction, the Director owned 4,151 shares meaning that the stake was reduced by 65.62% with the 7,923 share transaction.

The shares most recently traded at $13.91, up $0.91, or 6.54% since the insider transaction. Historical insider transactions for Renewable Energy Group go as follows:

  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 155,393
  • 24-Week # shares bought: 1,400
  • 24-Week # shares sold: 2.0 million

The average volume for Renewable Energy Group has been 585,500 shares per day over the past 30 days. Renewable Energy Group has a market cap of $510.0 million and is part of the basic materials sector and energy industry. Shares are up 138.74% year to date as of the close of trading on Tuesday.

Renewable Energy Group, Inc. produces biodiesel in the United States. The company operates through two segments, Biodiesel and Services. The company has a P/E ratio of 3.3. Currently there are 4 analysts that rate Renewable Energy Group a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGI - FREE

TheStreet Quant Ratings rates Renewable Energy Group as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Renewable Energy Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Euronet Worldwide (EEFT) - FREE Research Report

Brown Michael J who is Chief Executive Officer at Euronet Worldwide sold 2,100 shares at $43.04 on Nov. 12, 2013. Following this transaction, the Chief Executive Officer owned 1.9 million shares meaning that the stake was reduced by 0.11% with the 2,100 share transaction.

The shares most recently traded at $43.76, up $0.72, or 1.65% since the insider transaction. Historical insider transactions for Euronet Worldwide go as follows:

  • 4-Week # shares sold: 63,129
  • 12-Week # shares sold: 72,694
  • 24-Week # shares sold: 262,358

The average volume for Euronet Worldwide has been 215,400 shares per day over the past 30 days. Shares are up 81.23% year to date as of the close of trading on Tuesday.

Euronet Worldwide, Inc. provides payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company operates in three segments: EFT Processing, epay, and Money Transfer. The company has a P/E ratio of 33.9. Currently there are 3 analysts that rate Euronet Worldwide a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EEFT - FREE

TheStreet Quant Ratings rates Euronet Worldwide as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Euronet Worldwide Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Evercore Partners (EVR) - FREE Research Report

Sibbald Andrew who is CEO EVR Partners International at Evercore Partners sold 63,567 shares at $52.36 on Nov. 12, 2013. Following this transaction, the CEO EVR Partners International owned 266,562 shares meaning that the stake was reduced by 19.26% with the 63,567 share transaction.

The shares most recently traded at $52.11, down $0.25, or 0.49% since the insider transaction. Historical insider transactions for Evercore Partners go as follows:

  • 24-Week # shares sold: 20,000

The average volume for Evercore Partners has been 422,000 shares per day over the past 30 days. Evercore Partners has a market cap of $1.6 billion and is part of the financial sector and financial services industry. Shares are up 73.07% year to date as of the close of trading on Tuesday.

Evercore Partners Inc. operates as an independent investment banking advisory firm. The company operates through two segments, Investment Banking and Investment Management. The stock currently has a dividend yield of 1.91%. The company has a P/E ratio of 33.9. Currently there are no analysts that rate Evercore Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EVR - FREE

TheStreet Quant Ratings rates Evercore Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Evercore Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Phew! We Survived September: Cramer's 'Mad Money' Recap (Fri 9/29/17)

Phew! We Survived September: Cramer's 'Mad Money' Recap (Fri 9/29/17)

West Pharmaceutical (WST) Stock Stumbling, Wells Fargo Downgrades

West Pharmaceutical (WST) Stock Stumbling, Wells Fargo Downgrades

2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space

2 Big Companies and 1 Small One to Target in the Pharma/Biotech Space

Strong And Under The Radar Today: West Pharmaceutical Services (WST)

Strong And Under The Radar Today: West Pharmaceutical Services (WST)